Pfizer/BioNTech show high immune response in a booster dose against Omicron in clinical trial for children 5-11 years

Grant Paulsen, MD, assistant professor, Division of Infectious Disease, Department of Pediatrics, Cincinnati Children's Hospital Medical Center in Ohio, and primary investigator for the hospital's clinical trial for a third dose (booster) for the Pfizer/BioNTech vaccine for COVID-19, discusses what the data might mean for children aged 5 to 11 years.